Integra Lifesciences Holdings Corp (NAS:IART)
$ 29 0.1 (0.35%) Market Cap: 2.29 Bil Enterprise Value: 1.79 Bil PE Ratio: 58.00 PB Ratio: 0.79 GF Score: 77/100

Integra Lifesciences Holdings Corp at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 11:30PM GMT
Release Date Price: $58.32 (-0.27%)
Robert Justin Marcus
JP Morgan Chase & Co, Research Division - Analyst

Hello, everyone. I'm Robbie Marcus, the medical device analyst here at JPMorgan. I'm very happy to introduce our next speaker, Pete Arduini, the CEO of Integra LifeSciences. Pete?

Peter J. Arduini
Integra LifeSciences Holdings Corporation - President, CEO & Director

Thanks, Robbie. Good afternoon, everyone. I hope everyone's doing well. I'll start off with giving a little bit of an overview. We have some safe harbor statements here as well as I'll be using some non-GAAP financial metrics to talk a little bit about our numbers.

Integra by the numbers, for those that may not know the company that well, we are a company that, based on our 2019 numbers, roughly about $1.5 billion of revenue, of which 65% is in our Codman Specialty Surgical business, which is a combination of specialty instrumentation as well as a broad array of products that a neurosurgeon would use on a regular basis. And then 35% of the business is our Orthopedics and Tissue Technologies business. The

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot